Evaluation of the antibacterial activity of poly-(d,l-lactide-co-glycolide) nanoparticles containing violacein
Source abstract
Abstract
Since violacein—an antibiotic, antiviral, and antiparasitic compound—exhibits poor solubility in water, polymeric poly-(d,l-lactide-co-glycolide) nanoparticles containing this compound improved its solubility and biological activity. The nanoparticles were prepared by the nanoprecipitation method and characterized in terms of average diameter, zeta potential, drug loading, polymer recovery, in vitro release kinetic, and in vitro antibacterial activity. Nanoparticles with diameters between 116 and 139 nm and negative-charged outer surfaces were obtained. Drug-loading efficiency and polymer recovery were 87 and 93%, respectively. In vitro release kinetics assays showed that violacein loaded in these nanoparticles has sustained release behavior until 5 days. Both free and nanoparticles-loaded violacein exhibited in vitro antibacterial activity against Staphylococcus aureus ATCC 29213 and ATCC 25923 strains and exhibiting around two to five times lower minimum inhibitory concentration (MIC) than free violacein, respectively. The encapsulated violacein was efficient against methicilin-resistant Staphylococcus aureus (MRSA) strains. No significant activity against Escherichia coli and Salmonella enterica was found.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Microbial Metabolism and Applications · Medicinal Plants and Neuroprotection · Phytochemistry and Bioactivity Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (34)
Show source-provided references
1. Bromberg N, Justo GZ, Haun M, Durán N, Ferreira CV (2005) Violacein cytotoxicity on human blood lymphocytes and effect on phosphatases. J Enzym Inhib Med Chem 20:449–45410.1080/14756360500273052 ↗
2. Bromberg N, Dreyfuss JL, Regatieri CV, Palladino MV, Durán N, Nader HB, Haun M, Justo GZ (2010) Growth inhibition and pro-apoptotic activity of violacein in Ehrlich ascites tumor. Chem Biol Interact 186:43–5210.1016/j.cbi.2010.04.016 ↗
3. CLSI—Committee for Clinical Laboratory Standards (2003) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 6th edn. CLSI, Wayne, USA
4. Cui F, Shi K, Zhang L, Tao A, Kawashima Y (2006) Biodegradable nanoparticles loaded with insulin-phospholipid complex for oral delivery: preparation, in vitro characterization and in vivo evaluation. J Control Release 114:242–25010.1016/j.jconrel.2006.05.013 ↗
5. Cury GG, Mobilon C, Stehling EG, Lancellotti M, Ramos MC, Martinez R, Brocchi M, Silveira WD (2009) Molecular typing of methicillin-resistant Staphylococcus aureus (MRSA) strains isolated in two metropolitan areas of São Paulo State, Southeast Brazil. Braz J Infect Dis 13:165–169
6. De Carvalho DD, Costa FT, Duran N, Haun M (2006) Cytotoxic activity of violacein in human colon cancer cells. Toxicol In Vitro 20:1514–152110.1016/j.tiv.2006.06.007 ↗
7. De Souza AO, Aily DCG, Sato DN, Durán N (1999) Atividade da violaceina in vitro sobre o Mycobacterium tuberculosis H37RA. Rev Inst Adolfo Lutz 58:59–6210.53393/rial.1999.58.36676 ↗
8. Demling RH, Waterhouse B (2007) The increasing problem of wound bacterial burden and infection in acute and chronic soft-tissue wounds caused by methicillin-resistant Staphylococcus aureus. J Burns Wounds 7:89–98
9. Durán N, Menck CF (2001) Chromobacterium violaceum: a review of pharmacological and industrial perspectives. Crit Rev Microbiol 27:201–22210.1080/20014091096747 ↗
10. Durán N, Justo GZ, Melo PS, De Azevedo MBM, Brito ARMMS, Almeida ABA, Haun M (2003) Evaluation of the antiulcerogenic activity of violacein and its modulation by the inclusion complexation with beta-cyclodextrin. Can J Physiol Pharmacol 81:387–39610.1139/y03-033 ↗
11. Durán N, Justo GZ, Ferreira CV, Melo PS, Cordi L, Martins D (2007a) Violacein: properties and biological activities. Biotechnol Appl Biochem 48:127–13310.1042/BA20070115 ↗
12. Durán N, Marcato PD, De Souza GD, Alves OL, Esposito E (2007b) Antibacterial effect of silver nanoparticles produced by fungal process on textile fabrics and their effluent treatment. J Biomed Nanotechnol 3:203–20810.1166/jbn.2007.022 ↗
13. Durán N, Marcato PD, Buffo CMS, De Azevedo MMM, Esposito E (2007c) Poly (epsilon-caprolactone)/propolis extract: microencapsulation and antibacterial activity evaluation. Pharmazie 62:287–290
14. Durán N, Alvarenga MA, Da Silva EC, Melo PS, Marcato PD (2008) Microencapsulation of antibiotic rifampicin in poly(3-hydroxybutyrate-co-3-hydroxyvalerate). Arch Pharmacal Res 31:1509–151610.1007/s12272-001-2137-7 ↗
15. Ferreira CV, Bos CL, Versteeg HH, Justo GZ, Durán N, Peppelenbosch MP (2004) Molecular mechanism of violacein-mediated human leukemia cell death. Blood 104:1459–146410.1182/blood-2004-02-0594 ↗
16. Gimenez IF, Anazetti MC, Melo PS, Haun M, De Azevedo MMM, Durán N, Alves OL (2005) Cytotoxicity on V79 and HL60 cell lines by thiolated-β-cyclodextrin-Au/violacein nanoparticles. J Biomed Nanotechnol 1:352–35810.1166/jbn.2005.041 ↗
17. Har-el YE, Kato Y (2007) Intracellular delivery of nanocarriers for cancer therapy. Curr Nanosci 3:329–33810.2174/157341307782418612 ↗
18. Jain KK (2008) Recent advances in nanooncology. Technol Cancer Res Treat 7:1–1310.1177/153303460800700101 ↗
19. Kodach LL, Bos CL, Durán N, Peppelenbosch MP, Ferreira CV, Hardwick JC (2006) Violacein synergistically increases 5-fluorouracil cytotoxicity, induces apoptosis and inhibits Akt-mediated signal transduction in human colorectal cancer cells. Carcinogenesis 27:508–51610.1093/carcin/bgi307 ↗
20. Kuroda M, Ohta T, Uchiyama I, Baba T, Yuzawa H, Kobayashi I, Cui L, Oguchi A, Aoki K, Nagai Y, Lian J, Ito T, Kanamori M, Matsumaru H, Maruyama A, Murakami H, Hosoyama A, Mizutani-Ui Y, Takahashi NK, Sawano T, Inoue R, Kaito C, Sekimizu K, Hirakawa H, Kuhara S, Goto S, Yabuzaki J, Kanehisa M, Yamashita A, Oshima K, Furuya K, Yoshino C, Shiba T, Hattori M, Ogasawara N, Hayashi H, Hiramatsu K (2001) Whole genome sequencing of meticillin-resistant Staphylococcus aureus. Lancet 357(9264):1225–124010.1016/S0140-6736(00)04403-2 ↗
21. Lopes SCP, Yara C, Justo GZ, Nogueira PA, Rodrigues FLS, Goelnitz U, Wunderlich G, Facchini G, Brocchi M, Durán N, Costa FTM (2009) Violacein extracted from Chromobacterium violaceum inhibits Plasmodium growth in vitro and in vivo. Antimicrob Agents Chemother 53:2149–215210.1128/AAC.00693-08 ↗
22. Marcato PD, Durán N (2008) New aspects of nanopharmaceutical delivery systems. J Nanosci Nanotechnol 8:2216–222910.1166/jnn.2008.274 ↗
23. McClelland M, Sanderson KE, Spieth J, Clifton SW, Latreille P, Courtney L, Porwollik S, Ali J, Dante M, Du F, Hou S, Layman D, Leonard S, Nguyen C, Scott K, Holmes A, Grewal N, Mulvaney E, Ryan E, Sun H, Florea L, Miller W, Stoneking T, Nhan M, Waterston R, Wilson RK (2001) Complete genome sequence of Salmonella enterica serovar Typhimurium LT2. Nature 413(6858):852–85610.1038/35101614 ↗
24. Melo PS, De Azevedo MMM, Frungillo L, Anazetti MC, Marcato PD, Marcato PD, Durán N (2009) Nanocytotoxicity: violacein and violacein-loaded poly(d,l-lactide-co-glycolide) nanoparticles acting on human leukemic cells. J Biomed Nanotechnol 5:192–20110.1166/jbn.2009.1018 ↗
25. Mosqueira VC, Legrand P, Pinto-Alphandary H, Puisieux F, Barratt G (2000) Poly(d, l-lactide) nanocapsules prepared by a solvent displacement process: influence of the composition on physicochemical and structural properties. J Pharm Sci 89:614–62610.1002/(SICI)1520-6017(200005)89:5<614::AID-JPS7>3.0.CO;2-7 ↗
26. Murray CK (2008) Infectious disease complications of combat-related injuries. Crit Care Med 36:S358–S36410.1097/CCM.0b013e31817e2ffc ↗
27. Nair LS, Laurencin CT (2007) Biodegradable polymers as biomaterials. Prog Polym Sci 32:762–79810.1016/j.progpolymsci.2007.05.017 ↗
28. Powell JP, Wenzel RP (2008) Antibiotic options for treating community-acquired MRSA. Expert Rev Anti Infect Ther 6:299–30710.1586/14787210.6.3.299 ↗
29. Rettori D, Durán N (1998) Production, extraction and purification of violacein: an antibiotic pigment produced by Chromobacterium violaceum. World J Microbiol Biotechnol 14:685–68810.1023/A:1008809504504 ↗
30. Schaffazick SR, Guterres SSU, Freitas LD, Polhmann AR (2003) Physicochemical characterization and stability of the polymeric nanoparticle systems for drug administration. Quimica Nova 26:726–73710.1590/S0100-40422003000500017 ↗
31. Sievert DM, Rudrik JT, Patel JB, McDonald LC, Wilkins MJ, Hageman JC (2008) Vancomycin-resistant Staphylococcus aureus in the United States 2002–2006. Clin Infect Dis 46:668–67410.1086/527392 ↗
32. Soares MJ, Teixeira LA, Nunes MR, da Silva Carvalho MC, Ferreira-Carvalho BT, Figueiredo AM (2001) Analysis of different molecular methods for typing methicillin-resistant Staphylococcus aureus isolates belonging to the Brazilian epidemic clone. J Med Microbiol 50:732–74210.1099/0022-1317-50-8-732 ↗
33. WHO—World Health Organization (2008) available at www.who.org . Accessed 23 Aug 2008
34. Zhang YQ, Ren SX, Li HL, Wang YX, Fu G, Yang J, Qin ZQ, Miao YG, Wang WY, Chen RS, Shen Y, Chen Z, Yuan ZH, Zhao GP, Qu D, Danchin A, Wen YM (2003) Genome-based analysis of virulence genes in a non-biofilm-forming Staphylococcus epidermidis strain (ATCC 12228). Mol Microbiol 49:1577–159310.1046/j.1365-2958.2003.03671.x ↗